Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADMP POWR Grades
- ADMP scores best on the Growth dimension, with a Growth rank ahead of 69.62% of US stocks.
- The strongest trend for ADMP is in Momentum, which has been heading down over the past 31 weeks.
- ADMP's current lowest rank is in the Quality metric (where it is better than 2.67% of US stocks).
ADMP Stock Summary
- Adamis Pharmaceuticals Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.01% of US listed stocks.
- With a year-over-year growth in debt of 68.15%, Adamis Pharmaceuticals Corp's debt growth rate surpasses 88.44% of about US stocks.
- In terms of volatility of its share price, ADMP is more volatile than 85.87% of stocks we're observing.
- Stocks that are quantitatively similar to ADMP, based on their financial statements, market capitalization, and price volatility, are SREV, NURO, AMSC, NAOV, and MTRX.
- ADMP's SEC filings can be seen here. And to visit Adamis Pharmaceuticals Corp's official web site, go to www.adamispharmaceuticals.com.
ADMP Price Target
For more insight on analysts targets of ADMP, see our ADMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $1.25 | Average Broker Recommendation | 2 (Hold) |
ADMP Stock Price Chart Interactive Chart >
ADMP Price/Volume Stats
| Current price | $1.07 | 52-week high | $2.34 |
| Prev. close | $1.10 | 52-week low | $0.38 |
| Day low | $1.04 | Volume | 2,988,885 |
| Day high | $1.10 | Avg. volume | 14,717,625 |
| 50-day MA | $0.82 | Dividend yield | N/A |
| 200-day MA | $0.85 | Market Cap | 159.04M |
Adamis Pharmaceuticals Corporation (ADMP) Company Bio
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.
Latest ADMP News From Around the Web
Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.
Adamis Files Definitive Proxy Statement and Sends Letter to StockholdersSAN DIEGO, Jun 14, 2021--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent the below letter to stockholders. The letter has been signed by all five members of the Company’s Board of Directors: Howard C. Birndorf, Roshawn Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams. |
Is Adamis Pharmaceuticals Corporation (ADMP) Going to Burn These Hedge Funds?Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […] |
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Company’s experimental drug, in the treatment of COVID-19. Adamis is carrying out these activities with a large clinical research organization (CRO). Commenced activities include site |
Adamis Provides Update on ZIMHI™FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose. Adamis received FDA correspondence relating to th |
Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19Adamis Pharmaceuticals (ADMP) jumps 9% premarket following an announcement that the National Institutes of Health ((NIH)) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19.According to a study of cell cultures conducted by NIH, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity of a... |
ADMP Price Returns
| 1-mo | 42.44% |
| 3-mo | 3.88% |
| 6-mo | 116.29% |
| 1-year | 74.44% |
| 3-year | -71.66% |
| 5-year | -64.69% |
| YTD | 120.57% |
| 2020 | -30.74% |
| 2019 | -68.87% |
| 2018 | -48.86% |
| 2017 | 39.68% |
| 2016 | -41.67% |
Continue Researching ADMP
Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...